Register for our free email digests:
Latest From Able Laboratories Inc.
Sun Pharmaceutical Industries has started the integration of its opiates business in Australia, acquired earlier this year from GlaxoSmithKline, following the completion of the deal.
Sun Pharmaceutical Industries has acquired GlaxoSmithKline's opiates business in Australia – a move that is expected to help the Indian firm build significantly on its interests in the controlled substances space.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- Diamyd Medical AB
- Western Europe
- Parent & Subsidiaries
- Mertiva AB
- Senior Management
Andreas Bergsten, CEO
Anna Styrud, CFO
Erika Hillborg, Sr. Dir., Clin. Dev.
- Contact Info
Phone: (46) 8 661 00 26
Stockholm, SE-115 26
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.